» Articles » PMID: 1655405

Scatter Factor and Hepatocyte Growth Factor Are Indistinguishable Ligands for the MET Receptor

Overview
Journal EMBO J
Date 1991 Oct 1
PMID 1655405
Citations 196
Authors
Affiliations
Soon will be listed here.
Abstract

Scatter Factor (SF) is a fibroblast-secreted protein which promotes motility and matrix invasion of epithelial cells. Hepatocyte Growth Factor (HGF) is a powerful mitogen for hepatocytes and other epithelial tissues. SF and HGF, purified according to their respective biological activities, were interchangeable and equally effective in assays for cell growth, motility and invasion. Both bound with identical affinities to the same sites in target cells. The receptor for SF and HGF was identified as the product of the MET oncogene by: (i) ligand binding and coprecipitation in immunocomplexes; (ii) chemical crosslinking to the Met beta subunit; (iii) transfer of binding activity in insect cells by a baculovirus carrying the MET cDNA; (iv) ligand-induced tyrosine phosphorylation of the Met beta subunit. SF and HGF cDNA clones from human fibroblasts, placenta and liver had virtually identical sequences. We conclude that the same molecule (SF/HGF) acts as a growth or motility factor through a single receptor in different target cells.

Citing Articles

The MET Oncogene: An Update on Targeting Strategies.

Gallo S, Folco C, Crepaldi T Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598385 PMC: 11597589. DOI: 10.3390/ph17111473.


Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions.

Wang K, Hsu R Antibodies (Basel). 2024; 13(4).

PMID: 39449330 PMC: 11503282. DOI: 10.3390/antib13040088.


The rapidly changing field of predictive biomarkers of non-small cell lung cancer.

Toth L, Mokanszki A, Mehes G Pathol Oncol Res. 2024; 30:1611733.

PMID: 38953007 PMC: 11215025. DOI: 10.3389/pore.2024.1611733.


MET Oncogene Targeting for Cancer Immunotherapy.

Lombardi A, Sangiolo D, Vigna E Int J Mol Sci. 2024; 25(11).

PMID: 38892318 PMC: 11173045. DOI: 10.3390/ijms25116109.


The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy.

Crepaldi T, Gallo S, Comoglio P Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675409 PMC: 11054789. DOI: 10.3390/ph17040448.


References
1.
Ponzetto C, Giordano S, Peverali F, Della Valle G, Abate M, Vaula G . c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene. 1991; 6(4):553-9. View

2.
Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A . Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342(6248):440-3. DOI: 10.1038/342440a0. View

3.
Klein R, Jing S, Nanduri V, ORourke E, Barbacid M . The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991; 65(1):189-97. DOI: 10.1016/0092-8674(91)90419-y. View

4.
Rodrigues G, Naujokas M, Park M . Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol. 1991; 11(6):2962-70. PMC: 360125. DOI: 10.1128/mcb.11.6.2962-2970.1991. View

5.
Iyer A, Kmiecik T, Park M, Daar I, Blair D, Dunn K . Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ. 1990; 1(2):87-95. View